Seaport Therapeutics CEO Discusses IPO Success on 400th Episode of Biotech Podcast
Seaport Therapeutics CEO Daphne Zohar joins the 400th episode of 'The Readout LOUD' to discuss the biotech's successful IPO. The episode also covers t...
Xeber.world
Novo Nordisk
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Novo Nordisk's Wegovy Pill Drives Sales Boom, Boosts 2026 Outlook Amid GLP-1 Competition
Novo Nordisk’s new weight-loss pill, Wegovy, has achieved 1.3 million prescriptions in Q1 2026, prompting the company to raise its full-year guidance....
Novo Nordisk’s Wegovy Pill Boosts Earnings and Share Price After Upward Guidance Revision
Novo Nordisk revised its 2024 sales and operating profit guidance upward following strong performance of its Wegovy obesity drug. The Danish pharma gi...
France Fines Novo Nordisk and Eli Lilly Over Misleading Weight Loss Drug Ads
France’s medicines regulator has fined Novo Nordisk $2 million and Eli Lilly $127,000 for allegedly misleading advertisements for their weight loss dr...
FDA Proposes Ban on Compounded Weight-Loss Drugs, Targeting Semaglutide and Tirzepatide
The FDA has proposed excluding semaglutide and tirzepatide, key ingredients in popular weight-loss and diabetes drugs like Wegovy, Ozempic, Mounjaro,...
Medicare Scraps Obesity Drug Pilot After Insurer Pushback; Amazon Launches GLP-1 Access Program
The Trump administration's Medicare obesity drug pilot was abandoned after insurers declined to participate. Meanwhile, Amazon's One Medical is launch...
Trump Administration's Medicare Weight Loss Drug Pilot Rejected by Insurers, Government to Cover Costs Separately
The Trump administration proposed a Medicare pilot program to offer discounted weight loss drugs to seniors, but insurers declined participation. As a...
FDA Approves Higher Dose Wegovy Injection for Enhanced Weight Loss Results
The FDA has approved a 7.2 mg weekly dose of Wegovy, a GLP-1 medication, for weight loss. Clinical trials show this higher dose can lead to 25% more w...